BRAF and colorectal carcinoma: Observed associations between SARIFA-positivity and CRC-specific as well as overall survival were stronger in the BRAF mutation subgroup compared with the BRAF wild-type subgroup (CRC-specific: HRBRAF,mut: 1.68; 95% CI: 1.14-2.49 vs. HRBRAF,wt: 1.55; 95% CI: 1.29-1.86; overall: HRBRAF,mut: 1.70; 95% CI: 1.23-2.36 vs. HRBRAF,wt: 1.35; 95% CI: 1.16-1.58; Table 1).